57 related articles for article (PubMed ID: 9198247)
1. GPIIb/IIIa antagonists: pathophysiologic and therapeutic insights from studies of c7E3 Fab.
Coller BS
Thromb Haemost; 1997 Jul; 78(1):730-5. PubMed ID: 9198247
[TBL] [Abstract][Full Text] [Related]
2. New antiplatelet agents: platelet GPIIb/IIIa antagonists.
Coller BS; Anderson K; Weisman HF
Thromb Haemost; 1995 Jul; 74(1):302-8. PubMed ID: 8578476
[TBL] [Abstract][Full Text] [Related]
3. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. European Cooperative Study Group.
Simoons ML; de Boer MJ; van den Brand MJ; van Miltenburg AJ; Hoorntje JC; Heyndrickx GR; van der Wieken LR; de Bono D; Rutsch W; Schaible TF
Circulation; 1994 Feb; 89(2):596-603. PubMed ID: 7508826
[TBL] [Abstract][Full Text] [Related]
4. Use of GPIIb/IIIa inhibitors in cardiovascular medicine.
Ahrens I; Peter K; Bode C
Expert Rev Cardiovasc Ther; 2003 Jul; 1(2):233-42. PubMed ID: 15030283
[TBL] [Abstract][Full Text] [Related]
5. The anti-GPIIb-IIIa agents: fundamental and clinical aspects.
Coller BS; Anderson KM; Weisman HF
Haemostasis; 1996 Oct; 26 Suppl 4():285-93. PubMed ID: 8979134
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and "clinical restenosis".
Reverter JC; Béguin S; Kessels H; Kumar R; Hemker HC; Coller BS
J Clin Invest; 1996 Aug; 98(3):863-74. PubMed ID: 8698879
[TBL] [Abstract][Full Text] [Related]
7. [Modern "antiplatelet agents" in unstable angina].
Vahanian A; Garbarz E
Arch Mal Coeur Vaiss; 1996 Nov; 89(11 Suppl):1521-6. PubMed ID: 9092413
[TBL] [Abstract][Full Text] [Related]
8. Sudden onset of EDTA-dependent pseudothrombocytopenia after therapy with the glycoprotein IIb/IIIa antagonist c7E3 Fab.
Stiegler H; Fischer Y; Steiner S; Strauer BE; Reinauer H
Ann Hematol; 2000 Mar; 79(3):161-4. PubMed ID: 10803940
[TBL] [Abstract][Full Text] [Related]
9. Emergency coronary artery bypass graft surgery in abciximab-treated patients.
Lemmer JH; Metzdorff MT; Krause AH; Martin MA; Okies JE; Hill JG
Ann Thorac Surg; 2000 Jan; 69(1):90-5. PubMed ID: 10654493
[TBL] [Abstract][Full Text] [Related]
10. Abciximab (ReoPro) removal with a hemoconcentrator during cardiopulmonary bypass.
Lemmer JH
J Thorac Cardiovasc Surg; 1999 Nov; 118(5):980-1. PubMed ID: 10534719
[No Abstract] [Full Text] [Related]
11. The effects of GPIIb-IIIa antagonists and a combination of three other antiplatelet agents on platelet-leukocyte interactions.
Zhao L; Bath PM; Fox S; May J; Judge H; Lösche W; Heptinstall S
Curr Med Res Opin; 2003; 19(3):178-86. PubMed ID: 12803731
[TBL] [Abstract][Full Text] [Related]
12. Effects of platelets and white blood cells and antiplatelet agent C7E3 (Reopro) on a new test of PAF procoagulant activity of whole blood.
Despotis GJ; Ikonomakou S; Levine V; Joiner-Maier D; Santoro SA; Joist JH
Thromb Res; 1997 May; 86(3):205-19. PubMed ID: 9175242
[TBL] [Abstract][Full Text] [Related]
13. Abciximab (ReoPro) removal during cardiopulmonary bypass with a hemoconcentrator.
Steinhubl SR; Moore SA; Lincoff AM
J Thorac Cardiovasc Surg; 2000 Feb; 119(2):401-2. PubMed ID: 10649221
[No Abstract] [Full Text] [Related]
14. Safety of abciximab during percutaneous coronary intervention in patients with chronic renal insufficiency.
Jeremias A; Bhatt DL; Chew DP; Ziada KM; Albirini A; Brener SJ; Lincoff AM; Topol EJ; Ellis SG
Am J Cardiol; 2002 May; 89(10):1209-11. PubMed ID: 12008179
[No Abstract] [Full Text] [Related]
15. Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?
Califf RM
Stat Med; 2002 Oct; 21(19):2889-97. PubMed ID: 12325105
[TBL] [Abstract][Full Text] [Related]
16. [Drug-induced thrombocytopenia].
Hangaishi A; Kurokawa M
Nihon Rinsho; 2007 Oct; 65 Suppl 8():465-9. PubMed ID: 18074583
[No Abstract] [Full Text] [Related]
17. Major bleeding and severe thrombocytopenia after combined heparin and abciximab-c7E3 Fab therapy.
Claeys LG; Berg W
Eur J Vasc Endovasc Surg; 2003 Jan; 25(1):85-7. PubMed ID: 12525818
[No Abstract] [Full Text] [Related]
18. Platelet GPIIb/IIIa antagonists: how safe is this antithrombotic approach?
Mousa SA; De Grado WF; Reilly TM
Am J Med; 1994 Mar; 96(3):300. PubMed ID: 8154520
[No Abstract] [Full Text] [Related]
19. Potent, selective, orally active 3-oxo-1,4-benzodiazepine GPIIb/IIIa integrin antagonists.
Samanen JM; Ali FE; Barton LS; Bondinell WE; Burgess JL; Callahan JF; Calvo RR; Chen W; Chen L; Erhard K; Feuerstein G; Heys R; Hwang SM; Jakas DR; Keenan RM; Ku TW; Kwon C; Lee CP; Miller WH; Newlander KA; Nichols A; Parker M; Peishoff CE; Rhodes G; Ross S; Shu A; Simpson R; Takata D; Yellin TO; Uzsinskas I; Venslavsky JW; Yuan CK; Huffman WF
J Med Chem; 1996 Dec; 39(25):4867-70. PubMed ID: 8960544
[No Abstract] [Full Text] [Related]
20. [Overview of recent monoclonal antibody therapy].
Ozeki I; Imai K
Nihon Rinsho; 2002 Mar; 60(3):457-62. PubMed ID: 11904958
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
